Lead Compound

Type: Keyphrase
Name: Lead Compound
First reported Sep 16 2014 - Updated 23 hours ago - 2 reports

Company News: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT

-      Field-based trial with 196 patients shows significant reductions in seasonal allergy symptoms-      Efficacy of AllerT in both dose groups maintained during the second birch pollen seasonAnergis , a company developing proprietary ultra-fast allergy ... [Published Akampion - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 16 2014 - 1 reports

Molecular Templates Announces Completion of $12M Series C Financing

., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapies, announced today that it has expanded its series C financing with an additional $3.5M investment from AJU IB Investment. Molecular Templates had ... [Published Wall Street Select - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Is Intercept Pharmaceuticals Building The Next Great Specialty Franchise?

By Stephen Simpson, CFA :As great as Alexion (NASDAQ: ALXN ) has shown itself to be with its orphan drug Soliris for rare kidney ailments, Intercept Pharmaceuticals (NASDAQ: ICPT ) may be establishing a similar path in the until-recently overlooked world ... [Published BioPortfolio - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 2 reports

Loxo Oncology Announces Second Quarter 2014 Financial Results

STAMFORD, Conn., Sept. 12, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today reported financial results for the quarter ... [Published Virtual Strategy Magazine - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 2 reports

Rock Creek Pharmaceuticals : Receives New Dietary Ingredient Notification (NDIN) Response

SARASOTA, Fla., Sept. 12, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. ... [Published 4 Traders - Sep 12 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 3 reports

ENDECE Neural to Present Updated NDC-1308 Data at ECTRIMS/ACTRIMS Meeting

ENDECE Neural announced today the forthcoming presentation of new, pre-clinical evidence that the company’s lead compound, NDC-1308, induces remyelination in vivo in a validated animal model of demyelination. The data…Click to Continue » ... [Published Fort Mills Times - Sep 09 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Arno Licenses U. Minn. Technology to Identify Likeliest Onapristone Patients

Arno Therapeutics said today it licensed from the University of Minnesota a cancer diagnostic technology designed to identify patients most likely to benefit from Arno's lead compound, a drug candidate now in a Phase I study.The technology is related ... [Published Genetic Engineering News - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Minerva Neurosciences to Present at Baird 2014 Health Care Conference

CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Minerva NeurosciencesA live audio webcast of the presentation will be available online from the investor relations section of the company's website at http://ir.minervaneurosciences.com. A replay of ... [Published BusinessWeek - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Celldex Offers A Broad Portfolio Of Oncology Solutions

By Scrying Biotech :While it's hard to take a company seriously that affectionately refers to its lead product candidates by the nicknames, Rindo, Glemba and Varli, Celldex Therapeutics (NASDAQ: CLDX ), headquartered in Hampton, NJ with research facilities ... [Published BioPortfolio - Aug 25 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 1 reports

Turning Car Batteries into Solar Cells

Lead has quite a history as the soft metal once saw many uses, such as water pipes to additives for gasoline and paint, but is now restricted to just a few, due to its potential health hazards. That is also why we see so many recycling programs specifically ... [Published Overclockers Club - Aug 19 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 4 reports

August 15, 2014: Santhera Receives CHF 13.4 Million Through Sale of Treasury Shares

The treasury shares with a par value of CHF 1.00 were issued from the Company's conditional capital. The newly issued shares represent 4.1% of the Company's total outstanding share capital of CHF 4,911,728."This additional capital provides us with a strong ... [Published Noodls - Aug 15 2014]
First reported Jul 22 2014 - Updated Jul 23 2014 - 3 reports

SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ... [Published EON Science - Jul 22 2014]

Quotes

Hatchtech CEO, Hugh Alsop said: "This is a very exciting result, providing clear evidence in support of the safety and efficacy of Xeglyze? Lotion, as well as the superior commercial potential of the product. Success with these studies now places Hatchtech in a strong position to seek marketing approval in the US as well as accelerate our plans for the commercialisation of Xeglyze Lotion. The company remains on track to file a New Drug Application with the US FoodFood and Drug Administration in the first half of 2015." About Hatchtech Hatchtech Pty Ltd is an Australian specialty pharmaceutical product company developing technology for the control of invertebrate pests...
"We are delighted to welcome Sandra to the Nora team," said Jeffrey K Tong, Ph D , President and CEO of Nora Therapeutics. "Her marketing and product launch experience, combined with her background in working with patients and physicians in areas of high unmet need, including orphan indications, will be invaluable to Nora as we continue advancing NT100 toward the marketplace as a potential new treatment option for women who have experienced multiple IVF failures or who have suffered from recurrent miscarriages."
"It's an honor to join SAGE Therapeutics at such an important time," said Mr. Cola. "With a successful IPO and the rapid development of its lead compound, SAGE-547, the company is poised to deliver new treatments for patients suffering from CNS disorders with few or no treatment options. I look forward to partnering with the SAGE team to expand and develop these efforts."
-- Robert Wodarczyk, President of Dig-it UndergroundDig-it Underground Inc., stated today, "With the legalization of adult use marijuana in the States of Colorado and Washington, the cannabis industry has seen continued growth and expansion."

More Content

All (172) | News (99) | Reports (0) | Blogs (60) | Audio/Video (0) | Fact Sheets (1) | Press Releases (12)
sort by: Date | Relevance
Synereca bags $1.4 mln [Published PE Hub Blog - 10 hours ago]
Celator(R) Pharmaceuticals to Ring the NASDAQ S... [Published GlobeNewswire: Acquisitions News - 13 hours ago]
Celator(R) Pharmaceuticals to Ring the NASDAQ S... [Published Tamar Securities - 13 hours ago]
Hatchtech Announces Successful Phase 3 Study Re... [Published Pharmacy Choice - 14 hours ago]
Nora Therapeutics Names Sandra Shpilberg Vice P... [Published GlobeNewswire: Acquisitions News - Sep 16 2014]
Nora Therapeutics Names Sandra Shpilberg Vice P... [Published RCL Advisors - Sep 16 2014]
Company News: Anergis Reports Positive Long-Ter... [Published Akampion - Sep 16 2014]
Nuvo Research: An Overlooked Stock With Great U... [Published Seeking Alpha - Sep 16 2014]
Synereca Pharmaceuticals Announces Financing Le... [Published Industrial Info Financials - Sep 16 2014]
SAGE Therapeutics Appoints Michael F. Cola to t... [Published EMoneyDaily - Sep 16 2014]
Anergis Reports Positive Long-Term Clinical Eff... [Published Live-PR.com - Sep 16 2014]
FDA Approves Baxter's RIXUBIS; TG Therapeutics ... [Published BioMedReports - Sep 16 2014]
Is Intercept Pharmaceuticals Building The Next ... [Published BioPortfolio - Sep 15 2014]
Is Intercept Pharmaceuticals Building The Next ... [Published Seeking Alpha - Sep 15 2014]
Drawbridge Pharmaceuticals To Present Clinical ... [Published BioSpace - Sep 15 2014]
Molecular Templates grabs $3.5 mln Series C [Published PE Hub Blog - Sep 15 2014]
TetraLogic Pharmaceuticals Announces Preclinica... [Published Noodls - Sep 15 2014]
Molecular Templates Announces Completion of $12... [Published Wall Street Select - Sep 15 2014]
Celator(R) Pharmaceuticals Announces Publicatio... [Published Tamar Securities - Sep 15 2014]
Tekmira: Much More Than An Ebola Treatment [Published Seeking Alpha - Sep 15 2014]
Vicus phase II study in India reports survival ... [Published PharmaBiz - Sep 13 2014]
Rock Creek Pharmaceuticals : Receives New Dieta... [Published 4 Traders - Sep 12 2014]
Rock Creek Pharmaceuticals Receives New Dietary... [Published TickerTech.com - Sep 12 2014]
Loxo Oncology Announces Second Quarter 2014 Fin... [Published Virtual Strategy Magazine - Sep 12 2014]
Vicus Therapeutics' VT-122 improves overall sur... [Published Drug Discovery News - Sep 12 2014]
Loxo Oncology Announces Second Quarter 2014 Fin... [Published Pettinga Financial Advisors - Sep 12 2014]
ASLAN Commences Taiwan Trials For Gastric Cance... [Published Asian Scientist - Sep 12 2014]
Hatchtech Announces Successful Phase 3 Study Re... [Published HispanicBusiness.com - Sep 10 2014]
Cellectar Biosciences gets FDA green light for ... [Published Drug Discovery News - Sep 10 2014]
Palatin Technologies, Inc. (PTN) CEO Carl Spana... [Published Seeking Alpha - Sep 09 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Synereca bags $1.4 mln [Published PE Hub Blog - 10 hours ago]
Synereca Pharmaceutics has received $1.4 million in debt financing. Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, led the round with participation from i2E . Based in Oklahoma City, Synereca is a biopharmaceutical ...
Molecular Templates grabs $3.5 mln Series C [Published PE Hub Blog - Sep 15 2014]
Molecular Templates has secured an additional $3.5 million in Series C funding from AJU IB Investment. In conjunction with the funding, Timothy Sullivan, a partner at AJU Life Sciences Overseas Expansion Platform Fund, has been added to the firm’s ...
ENDECE Neural to Present Updated NDC-1308 Data ... [Published Business Wire Health News - Sep 09 2014]
MEQUON, Wis.--(BUSINESS WIRE)--ENDECE will present new, pre-clinical data for its lead compound, NDC-1308, inducing remyelination in vivo in animal model of demyelination at a poster session at the 2014 ACTRIMS/ECTRIMS meeting. ...
Phosphatidic acid promotes remyelination [Published Multiple Sclerosis Research - Aug 12 2014]
Yamamoto S, Gotoh M, Kawamura Y, Yamashina K, Yagishita S, Awaji T, Tanaka M, Maruyama K, Murakami-Murofushi K, Yoshikawa K. Cyclic phosphatidic acid treatment suppress cuprizone-induced demyelination and motor dysfunction in mice. Eur J Pharmacol. 2014. ...
SAGE Therapeutics Receives Fast Track Designati... [Published EON Science - Jul 22 2014]
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--SAGE Therapeutics (NASDAQ: SAGE) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation to the SAGE-547 development program to treat status epilepticus. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Celator(R) Pharmaceuticals to Ring the NASDAQ S... [Published GlobeNewswire: Acquisitions News - 13 hours ago]
Nora Therapeutics Names Sandra Shpilberg Vice P... [Published GlobeNewswire: Acquisitions News - Sep 16 2014]
Rich Pharmaceuticals Hires Contract Research Or... [Published GlobeNewswire: Advertising News - Jul 23 2014]
Nora Therapeutics Presents Phase 1 Data on NT10... [Published GlobeNewswire: Advertising News - Jun 30 2014]
Cara Therapeutics Announces Appointment of Robe... [Published GlobeNewswire: Advertising News - Jun 24 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.